CLLS
Cellectis
Halal Rating :
Last Price
$1.49
Last updated:
Market Cap
-
7D Change
-11.61%
1 Year Change
-45.8%
Company Overview
Industries
Exchange
Next Earnings Date
Cellectis is a clinical-stage biotechnology company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells. The company uses its TALEN® gene-editing technology to create innovative cell and gene therapies for treating various diseases, particularly in oncology.
The company's main focus is on developing off-the-shelf CAR T-cell product candidates for treatment of various cancers. Their pipeline includes several product candidates in various stages of clinical development.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Cellectis's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.